← Browse by Condition
Medical Condition
metastatic malignant solid neoplasm
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 4, Phase 1
ClinicalMetric tracks all active clinical trials for metastatic malignant solid neoplasm sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — metastatic malignant solid neoplasm Clinical Trials
How many clinical trials are currently recruiting for metastatic malignant solid neoplasm?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for metastatic malignant solid neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for metastatic malignant solid neoplasm?
metastatic malignant solid neoplasm research spans Phase 1 (2 trials), Phase 2 (3 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a metastatic malignant solid neoplasm clinical trial?
Eligibility criteria for metastatic malignant solid neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 3
Phase 4 1
Top Sponsors
4 trials
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06349642
Recruiting
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Enrollment
324 pts
Location
United States
Sponsor
Mayo Clinic
NCT03907475 Phase 2
Recruiting
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Enrollment
115 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT05564377 Phase 2
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Enrollment
2,900 pts
Location
United States, Puert...
Sponsor
National Cancer Institute (NCI...
NCT05059678
Recruiting
Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
Enrollment
120 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT07405086 Phase 4
Recruiting
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Enrollment
160 pts
Location
United States
Sponsor
OHSU Knight Cancer Institute
NCT05803382 Phase 1
Recruiting
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Enrollment
30 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT05691491 Phase 1, Phase 2
Recruiting
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Enrollment
58 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology